These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17177184)

  • 1. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease.
    Huang X; Chen H; Miller WC; Mailman RB; Woodard JL; Chen PC; Xiang D; Murrow RW; Wang YZ; Poole C
    Mov Disord; 2007 Feb; 22(3):377-81. PubMed ID: 17177184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals.
    Lv Y; Xu B; Zhang X; Chen C; Gao Y; Li N
    Brain Behav; 2022 Jan; 12(1):e2454. PubMed ID: 34894416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serum lipid profile of Parkinson's disease patients: a study from China.
    Guo X; Song W; Chen K; Chen X; Zheng Z; Cao B; Huang R; Zhao B; Wu Y; Shang HF
    Int J Neurosci; 2015; 125(11):838-44. PubMed ID: 25340257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study.
    Huang X; Abbott RD; Petrovitch H; Mailman RB; Ross GW
    Mov Disord; 2008 May; 23(7):1013-1018. PubMed ID: 18381649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.
    Lamarche B; Tchernof A; Mauriège P; Cantin B; Dagenais GR; Lupien PJ; Després JP
    JAMA; 1998 Jun; 279(24):1955-61. PubMed ID: 9643858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased Serum Lipid Levels and Ratios Correlate with Low Prevalence of Coronary Heart Disease in Patients with Parkinson's Disease.
    Bao M; Hu R; Chen Y; Wang N; Xue H; He J; Jin J; Kong W; Ke G; Xue Q
    Clin Lab; 2018 Sep; 64(9):1413-1419. PubMed ID: 30274018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term statin use and the risk of Parkinson's disease.
    Friedman B; Lahad A; Dresner Y; Vinker S
    Am J Manag Care; 2013 Aug; 19(8):626-32. PubMed ID: 24304212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.
    Rozani V; Gurevich T; Giladi N; El-Ad B; Tsamir J; Hemo B; Peretz C
    Mov Disord; 2018 Aug; 33(8):1298-1305. PubMed ID: 30145829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma fasting and nonfasting triglycerides and high-density lipoprotein cholesterol in atherosclerotic stroke: different profiles according to low-density lipoprotein cholesterol.
    Kim SJ; Park YG; Kim JH; Han YK; Cho HK; Bang OY
    Atherosclerosis; 2012 Aug; 223(2):463-7. PubMed ID: 22683121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low LDL cholesterol,
    Benn M; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
    BMJ; 2017 Apr; 357():j1648. PubMed ID: 28438747
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
    Whelton SP; Meeusen JW; Donato LJ; Jaffe AS; Saenger A; Sokoll LJ; Blumenthal RS; Jones SR; Martin SS
    J Clin Lipidol; 2017; 11(4):1065-1072. PubMed ID: 28826567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
    Chasman DI; Giulianini F; MacFadyen J; Barratt BJ; Nyberg F; Ridker PM
    Circ Cardiovasc Genet; 2012 Apr; 5(2):257-64. PubMed ID: 22331829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.
    Huang X; Alonso A; Guo X; Umbach DM; Lichtenstein ML; Ballantyne CM; Mailman RB; Mosley TH; Chen H
    Mov Disord; 2015 Apr; 30(4):552-9. PubMed ID: 25639598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.
    Munkhaugen J; Sverre E; Otterstad JE; Peersen K; Gjertsen E; Perk J; Gullestad L; Moum T; Dammen T; Husebye E
    Eur J Prev Cardiol; 2017 Jun; 24(9):981-989. PubMed ID: 28196429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
    Kronenberg F; Lingenhel A; Lhotta K; Rantner B; Kronenberg MF; König P; Thiery J; Koch M; von Eckardstein A; Dieplinger H
    Kidney Int; 2004 Jul; 66(1):348-54. PubMed ID: 15200443
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.